Australia markets closed

Catalyst Biosciences, Inc. (CBIO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.2500-0.1000 (-7.41%)
At close: 1:00PM EST
1.2700 +0.02 (+1.60%)
After hours: 04:28PM EST

Catalyst Biosciences, Inc.

611 Gateway Boulevard
Suite 710
South San Francisco, CA 94080
United States
650 871 0761
http://www.catalystbiosciences.com

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 56

Key executives

NameTitlePayExercisedYear born
Dr. Nassim Usman Ph.D.Pres, CEO & Director769.18kN/A1960
Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D.Consultant577.04kN/A1954
Seline MillerInterim Chief Financial & Principal Accounting OfficerN/AN/AN/A
Dr. Grant Blouse M.Sc., Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Ana KaporSr. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Dr. Tom Knudsen D.V.M., Ph.D.Sr. VP of Corp. Devel.N/AN/AN/A
Mr. Charles J. DemockoSr. VP of Regulatory Affairs & QualityN/AN/A1955
Dr. Anju Chatterji Ph.D.Sr. VP of Biologics Devel. & ManufacturingN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. The company's pipeline also includes a preclinical program partnered with Biogen International GmbH for dry age-related macular degeneration (AMD); factor I protease for SQ prophylaxis in patients with complement factor I deficiency and C4b-degraders designed to target disorders of the classical complement pathway, as well as other complement programs. The company also develops CB 4332 intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a C3 degrader product candidate in preclinical development for the treatment of dry AMD. It has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

Corporate governance

Catalyst Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.